{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-028414","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.579966+00:00","generated_at":"2026-06-21T09:25:21.487583+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Nuo Therapeutics shareholders approve all proposals at 2022 annual meeting","bullets":["Re-elected David E. Jorden, C. Eric Winzer, Scott M. Pittman, and Paul D. Mintz as directors.","Ratified Marcum LLP as independent auditor for FY2022 with 27,697,944 votes for, 1,074 against.","Advisory vote on executive compensation approved with 26,692,397 for, 5,370 against, 5,000 abstain.","Advisory vote on frequency set to every three years based on 23,767,794 votes for three years.","Approved amendment to 2016 Omnibus Incentive Compensation Plan with 26,188,825 for, 7,988 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-028414","json":"https://secwatch.observer/filing/0001437749-22-028414.json","markdown":"https://secwatch.observer/filing/0001437749-22-028414.md","text":"https://secwatch.observer/filing/0001437749-22-028414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/aurx20221202b_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:25:21.487583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09148e5a1904a118dcd850c408b47a9bdb621c8f","claim":"Nuo Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2022-12-02 meeting.","evidence_excerpt":"One Year Two Years Three Years Abstain 4. To approve, on an advisory basis, the frequency of the advisory vote on executive compensation 2,389,764 37,874 23,767,794 507,335","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-02"}],"fact_type":"shareholder_vote"},{"claim_id":"23f2b1c26685027955ae1b9a5581adebbb205939","claim":"Nuo Therapeutics, Inc. shareholders approved Ratification of the appointment of Marcum LLP as independent registered public accounting firm for fiscal year 2022 at the 2022-12-02 meeting.","evidence_excerpt":"For Withheld Abstain 2. To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 27,697,944 1,074 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-02"}],"fact_type":"shareholder_vote"},{"claim_id":"46199a778ac8d58ce5864adc92bd9c81d6e8e3bf","claim":"Nuo Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2022-12-02 meeting.","evidence_excerpt":"For Withheld Abstain 3. To approve, on an advisory basis, the compensation of the Company's named executive officers 26,692,397 5,370 5,000","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-02"}],"fact_type":"shareholder_vote"},{"claim_id":"e2dbf54c0469599c275446e8539748d7378f4edc","claim":"Nuo Therapeutics, Inc. shareholders approved Election of four directors to serve on the Board of Directors at the 2022-12-02 meeting.","evidence_excerpt":"1. Election of Directors For Withheld Broker Non-Votes David E. Jorden 26,699,444 3,323 996,251 C. Eric Winzer 26,198,490 504,277 996,251 Scott M. Pittman 26,199,444 503,323 996,251 Paul D. Mintz 26,199,444 503,323 996,251","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-02"}],"fact_type":"shareholder_vote"},{"claim_id":"e5102ce3cc20dcc940e85517d3c4e39d87504582","claim":"Nuo Therapeutics, Inc. shareholders approved Ratification and approval of the 2016 Omnibus Incentive Compensation Plan, as amended at the 2022-12-02 meeting.","evidence_excerpt":"For Withheld Abstain 5. To ratify and approve the Company's 2016 Omnibus Incentive Compensation Plan, as amended 26,188,825 7,988 505,954","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}